{"metadata":{"topics":["Accountability","Accountant","Accounting","Accounting standard","Act of God","Administrative law","Adverse event","Agreement (linguistics)","Algorithm","Alternative dispute resolution","Animal","Anti-competitive behaviour","Applied ethics","Arbitration","Artificial objects","Assay","Asset","Assignment (law)","Attention","Audit","Auditor's report","Bankruptcy","Bankruptcy in the United States","Beneficial interest","Biology","Biopharmaceutical","Biotechnology","Boston","Business","Business development","Business economics","Business ethics","Business law","Calendar","Cell (biology)","Certified Public Accountant","Chemical substance","Chief executive officer","Choice of law","Civil law (common law)","Civil law (legal system)","Clinical medicine","Clinical research","Clinical trial","Cognition","Cognitive science","Common law","Communication","Companies","Company","Comparative law","Competition (economics)","Composition of matter","Confidentiality","Conflict (process)","Conflict of interest","Consent","Consent decree","Construction","Consultant","Contract","Contract law","Contractual term","Copyright infringement","Corporate finance","Corporate governance","Corporate law","Corporate personhood","Corporation","Corporations","Cost","Counsel","Courier","Court","Covenant (law)","Credit","Creditor","Culture","Currency","Custom","Damages","Data","De minimis","Debarment","Debt","Debtor","Definition","Delaware","Dermatology","Disability","Disclaimer","Discovery (law)","Disease","Dispute resolution","Doctor (title)","Doctrines","Document","Documents","Dose (biochemistry)","Drafter","Drug Price Competition and Patent Term Restoration Act","Drug development","Drug discovery","Drugs","Duty of care","Economic law","Economic sectors","Economics of regulation","Economy","Economy of the United States","Efficacy","Emergence","Encumbrance","End user","Environmental law","Epistemology","Equity (law)","Ethical principles","Ethically disputed business practices","Ethics","European Medicines Agency","European Union","Evaluation","Evidence","Exchange rate","Exclusive right","Exercise","Existence","Expense","Experience","Expert witness","Export","Faith","Fax","Federal Trade Commission","Fee","Finance","Financial analyst","Financial economics","Financial markets","Financial problems","Financial services","Flood","Food","Food and Drug Administration","Force majeure","Frequency","General assignment","General counsel","Generally Accepted Accounting Principles (United States)","Generic drug","Glossary of patent law terms","God","Good faith","Government","Government agencies","Government agency","Government and personhood","Government information","Government institutions","Government-related organizations","Grammatical gender","Grammatical number","Gross negligence","Guarantee","Health","Health care","Health economics","Health policy","Health research","Health sciences","Healthcare industry","Healthcare quality","Hour","Human","Human activities","Human communication","Human rights","Immortalised cell line","Imperfect competition","Implied warranty","Import","Indemnity","Independent contractor","Indiana","Industries","Industry","Infection","Information","Information science","Injunction","Inquiry","Insolvency","Intangible assets","Intellectual property","Intellectual property law","Intellectual works","Interest","Interest rate","International relations","Invention","Invoice","Isomer","Jargon","Joint venture","Judgment (law)","Judiciaries","Jurisdiction","Jurisprudence","Justice","Justification","Know-how","Knowledge","Language","Law","Law and economics","Law of obligations","Lawsuit","Lawyer","Leadership","Legal communication","Legal concepts","Legal doctrines and principles","Legal documents","Legal ethics","Legal fictions","Legal liability","Legal literature","Legal procedure","Legal remedy","Legal writing","Liability (financial accounting)","License","Licenses","Lien","Life sciences","Life sciences industry","Light","Limited liability","Limited liability company","Liquidation","Local ordinance","Love","Mail","Management","Manufacturing","Market (economics)","Marketing","Matter","Mechanism of action","Medical diagnosis","Medical humanities","Medical research","Medical specialties","Medical treatments","Medication","Medicinal chemistry","Medicine","Mergers and acquisitions","Metaphysics","Methodology","Microeconomics","Milestone","Misappropriation","Misconduct","Model organism","Modulation","Molecule","Money","Moneyness","Monopoly (economics)","Morality","National security","Natural and legal rights","Natural resources law","Nature","Negligence","Negotiation","New Drug Application","New York (state)","New York City","Non-disclosure agreement","Number","Observation","Office action","Open government","Operation of law","Opinion","Option (finance)","Organization","Ownership","Paragraph","Partnership","Patent","Patent application","Patent claim","Patent infringement","Patent law","Patentability","Payment","Payments","Personal finance","Personality traits","Pharmaceutical industry","Pharmaceutical sciences","Pharmaceutics","Pharmacodynamics","Pharmacology","Pharmacovigilance","Pharmacy","Phases of clinical research","Philosophy","Phrase","Plural","Political economy","Political science","Politics","Power of attorney","Practice of law","Pre-clinical development","Prejudice (legal term)","Press release","Prevention","Preventive healthcare","Price","Principles","Privacy","Private law","Proclamation","Prodrug","Professional ethics","Prohibition","Property","Property law","Prosecutor","Prospectus (finance)","Provisional application","Prudential Tower","Psychological concepts","Psychology","Public administration","Public health","Public law","Public policy","Public records","Public sector","Public sphere","Quantity","Reason","Rebate (marketing)","Receipt","Receivership","Receptor (biochemistry)","Registered mail","Regulation","Regulatory agency","Regulatory compliance","Remittance","Research","Right of first refusal","Right to property","Rights","Royalty payment","Rule of law","Rules","Safety","Sales","Salt (chemistry)","Sanitization (classified information)","Science","Science and technology","Securities (finance)","Securities regulation in the United States","Security","Security (finance)","Security interest","Semiotics","Separation of powers","Service industries","Services (economics)","Severability","Signature","Social ethics","Social information processing","Social institutions","Social issues","Sociological theories","Software","Sources","Statute","Stock market","Strategic management","Subpoena","Supplementary protection certificate","Tax","Tax refund","Technology","Telephone","Telex","Term of patent in the United States","The Wall Street Journal","Theories of law","Therapy","Third-party beneficiary","Title (property)","Title 21 of the Code of Federal Regulations","Toxicity","Toxicology","Trade","Trade name","Trade secret","Trademark","Translation","Treaty","Trustee","Truth","U.S. Securities and Exchange Commission","Understanding","United States","United States Code","United States Department of Justice","United States dollar","Urban, rural, and regional economics","Value (ethics)","Vice President of the United States","Videotelephony","Virtue","Vitamin","Vitamin D","Volume","Waiver","Wall Street","War","Warranty","Weighted arithmetic mean","Wire transfer","Withholding tax","Witness","Written communication"],"person_names":["barclay kamb","esq","lester j. fagen","magen"],"vars":{"Party":{"LILLY":"[[Party 1]]"}},"organization_names":["and company","certified public accounting","cooley godward kronish llp","corporate center","development plan","european agency","first commercial sale","indemnitee","license authority","lily know-how","magen biosciences","magen biosciences inc.","magen biosciences, inc.","magen exclusivity period","magen force","magen technology","marketing authorization","net sales","patent responsibilities","permitted sellers","record retention","regulatory approval","royalty administration","schedule a","sr vice president corporate strategy","transfer","transferee"],"agreement_id":"7f062ee399e69557f1cf33a96ec16f9fed3b56de5dc1c56a5d954fb3cd62e991","terms":["***[rest of page left blank; signature page to follow]***","***“Agreement”***","***“Disclosing Party”***","***“Effective Date”***","***“Force Majeure”***","***“Indemnifying Party”***","***“Indemnitee”***","***“Magen”***","***“NDA”***","***“Parties.”***","***“Party”***","***“Patent Responsibilities”***","***“Receiving Party”***","***“Regulatory Documents”***","***“Remedies”***","***“SEC”***","***“[[ and ]]”***","**.**","**Additional Compound Option.**","**Additional Compounds**","**Adverse Event Reporting.**","**Amendment.**","**Application Date**","**Application Number**","**Assignability.**","**Audits.**","**By Magen.**","**Compliance with Law.**","**Conduct and Funding**","**Conduct of Defense.**","**Confidential Information.**","**Cooperation.**","**Country**","**Covenant Not to Sue**","**Defense of Action.**","**Development Reporting.**","**Disclosure of Agreement.**","**ELI [[ and ]] AND COMPANY**","**EXCLUSIVE LICENSE AGREEMENT**","**Encumbrance**","**Entire Agreement.**","**Exclusive Use of Licensed Compounds by Magen.**","**Exclusivity Regarding Dermatology Applications for VDRMs.**","**Force Majeure.**","**Governmental Filings.**","**IN WITNESS WHEREOF,**","**Indemnitee’s Separate Counsel.**","**Independent Contractor.**","**Initial License Fee****","**License Authority.**","**License.**","**Licensed Compounds**","**Limited Disclosure Permitted.**","**MAGEN BIOSCIENCES, INC.**","**Magen Right of First Refusal Option**","**Milestone Event**","**Milestone Payment**","**Milestone Payments.**","**NOW, THEREFORE,**","**No Benefit to Others.**","**No Debarment.**","**Notice.**","**Notices.**","**Patent Cooperation.**","**RECITALS**","**Record Retention, Royalty Reports, and Royalty Payment Schedule.**","**Regulatory Matters.**","**Representatives and Assistance.**","**SCHEDULE A**","**SCHEDULE B**","**SCHEDULE C**","**Schedule A  Licensed Compounds**","**Schedule B  Additional VDRM Compounds**","**Settlement.**","**Severability.**","**Sublicenses.**","**Supply of Compound.**","**Survival.**","**THIS EXCLUSIVE LICENSE AGREEMENT**","**Technology and Materials Transfer.**","**Term.**","**Trademarks.**","**Transfers Related to Regulatory Matters.**","**Transition Support.**","**Waiver.**","**[*","**[[Date 1: Date]]**","**and**","**between**","**“Additional Compound Option”**","**“Additional Compound”**","**“Affiliate”**","**“Applicable Laws”**","**“Calendar Quarter”**","**“Clinical Trial(s)”**","**“Confidential Information”**","**“Control”**","**“Damages”**","**“Data Exclusivity Period”**","**“Development Plan”**","**“Diligent Efforts”**","**“Effective Date”**","**“FDA”**","**“Field”**","**“First Commercial Sale”**","**“Force Majeure”**","**“GAAP”**","**“Information”**","**“Licensed Compound”**","**“Licensed Product”**","**“MAA”**","**“Magen Technology”**","**“Marketing Application”**","**“Net Sales”**","**“Patents”**","**“Permitted Seller”**","**“Person”**","**“Phase I Clinical Trials”**","**“Phase II Clinical Trials”**","**“Phase III Clinical Trials”**","**“Regulatory Approval”**","**“Regulatory Documents”**","**“Royalty Term”**","**“Territory”**","**“Third Person”**","**“Valid Claim”**","**“[[ and ]] Know-How”**","**“[[ and ]] Patents”**","*Wall Street Journal*","*]      [*","*] (*","*] ([*","*] (including at least [*","*] day exercise period, or (iii) the Parties fail to successfully negotiate and execute a licensing agreement for the Follow-On Compound, in the case Magen has exercised such Follow-On Option, then [[ and ]] shall be free to license the applicable Follow-On Compound to a Third Party, *","*] days after the Effective Date. Thereafter, during the term [[ and ]] will grant Magen access, during normal business hours, to appropriate [[ and ]] personnel (including [*","*] dollars ($[*","*] given their schedules and other responsibilities to [[ and ]] [*","*] million      [*","*] million to $[*","*] per calendar year so as to verify the accuracy of the information previously reported to [[ and ]] under Section 4.4. Any such audit shall be conducted by an independent certified public accounting firm of national standing selected by [[ and ]] and approved by Magen (which firm may be Magen’s independent certified public accounting firm), such approval not to be unreasonably withheld. Such audit may cover the period back to the beginning of two (2) full calendar years preceding the date of the request for such audit and may not cover any prior period. [[ and ]] may audit a given period of sales [*","*] percent ([*","*] to $[*","*]% of such payment against the royalties payable to [[ and ]] with respect to such Licensed Product, provided that in no event will the applicable royalty payable to [[ and ]] with respect to such Licensed Product be reduced by more than [*","*]%) of such amount owed, then the cost of the audit will be borne by Magen. Within [*","*]) for reasonable consultation related to the [[ and ]] Know-How not to exceed [*","*]) hours (in two hour increments) in total. If Magen requests consultation (by telephone or videoconference) beyond this amount, [[ and ]] will consider Magen’s request in light of the availability of Drs. [*","*]) or [*","*]) or in at least [*","*], [*","*]; however, if as a result of such audit the Parties agree that the actual amount of royalties owed to [[ and ]], for the period audited, is more than the amount of royalties paid by Magen for the period that is the subject of the audit by greater than [*","*bona fide*","*e.g.*","*except for*","*provided that*","*provided, however,*","“**Phase IIb Clinical Trials**”","“Additional Compound Option”","“Code”","“Failed Product”","“Follow-On Compounds”","“Follow-On Option”","“Magen Exclusivity Period”","“Replacement Product”","“Third Party License”","“Transferee”","“Transfer” ) all or a part of, [[ and ]]’s rights to the royalty payment and other payments referred to in Article 4 (the “Payment Rights”","“controlled by” and “under common control with”"]}}